Stockscreener 앱 받기
1.38%
전일 마감가:
$24.20
열려 있는:
$24.2
하루 거래량:
17.77M
Relative Volume:
0.38
시가총액:
$130.73B
수익:
$62.46B
순이익/손실:
$7.88B
주가수익비율:
17.29
EPS:
1.38
순현금흐름:
$9.84B
1주 성능:
+3.54%
1개월 성능:
+3.90%
6개월 성능:
-14.74%
1년 성능:
-14.19%
1일 변동 폭
$23.86
$24.25
1주일 범위
$22.46
$24.44
52주 변동 폭
$20.91
$31.54
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
PFE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
23.86 | 130.73B | 62.46B | 7.88B | 9.84B | 1.38 |
|
LLY
Lilly Eli Co
|
821.85 | 739.75B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.04 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
195.44 | 340.25B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
69.17 | 277.97B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
112.97 | 222.45B | 53.22B | 12.86B | 14.85B | 6.39 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
Pfizer Stock Up 5% Following Q1 Results: Time To Buy, Sell Or Hold? - Barchart.com
Analyst recommendations: Amazon, PepsiCo, Linde, Pfizer, Crowdstrike Holdings... - marketscreener.com
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Anti Suicide Drugs Market Detailed In New Research Report 2025 | - openPR.com
Is Pfizer Inc. (PFE) The Most Profitable Cheap Stock to Buy Now? - Insider Monkey
Is Pfizer Inc.'s (NYSE:PFE) Stock Price Struggling As A Result Of Its Mixed Financials? - Yahoo Finance
West Virginia counties, cities to receive Pfizer settlement checks - WBOY.com
CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (May 2025) - 24/7 Wall St.
Drug Discovery Market Is Booming So Rapidly 2025-2032Pfizer - openPR.com
Pfizer Inc (PFE-N) Stock Price and News - The Globe and Mail
Do Wall Street Analysts Like Pfizer Stock? - Nasdaq
Zacks.com featured highlights Centene, Pediatrix Medical, Pfizer, StoneCo and Banco Santander - Yahoo Finance
Pfizer donates $250K to Oklahoma Tribal health clinics - The Journal Record
What's Next For Pfizer Stock After A Mixed Q1? - Nasdaq
Judge Keeps Pfizer Foe's COVID Vaccine Patent Case Alive - Law360
Pfizer CEO Tariff Uncertainty Hinders U.S. Investments - MSN
Pfizer CEO Albert Bourla Emphasizes National Security In US Drug Manufacturing - Benzinga
Pfizer (NYSE:PFE) Reports Q1 Earnings, Reaffirms 2025 Revenue Guidance at US$61-64 Billion - Yahoo Finance
Pfizer (PFE) Rating Upgraded: Signs of Stabilization Amid Strate - GuruFocus
Pfizer, BioNTech Fail to Void Alnylam’s Covid-Shot Patent Claims - Bloomberg Law News
Pfizer donates $750,000 to tribal health centers in Oklahoma - News On 6
Ibuprofen Drug Market Deep Research Report with Forecast by 2032 | Pfizer Inc., Johnson & Johnson, Bayer AG - openPR.com
Pfizer Inc. (NYSE:PFE) Q1 2025 Earnings Call Transcript - Insider Monkey
Is Pfizer Stock A Buy Or A Sell On Its Massive Savings Plan? - Investor's Business Daily
Fentanyl Drug Market Deep Research Report with Forecast by 2032 | - openPR.com
Pfizer Pulls Plug on Weight-Loss Pill Amid Health Concerns - CEO Today
Pfizer shifts to cost-cutting, new drug research after weight-loss bet fizzles - Crain's New York Business
Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - Yahoo Finance
Pfizer's Q1 Update May Mark A Bottom In The Stock (NYSE:PFE) - Seeking Alpha
Pfizer (PFE) Exceeds EPS Expectations, Faces Revenue Challenges - GuruFocus
Pfizer Inc (PFE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline and Strategic Growth - Yahoo Finance
Pfizer Reports Strong Q1 2025 Results and Reaffirms Guidance - TipRanks
Pfizer's CEO said the company could make 'tremendous investments' in the US if Trump's tariffs go away - Business Insider
Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations? - Yahoo Finance
Pfizer’s Earnings Call: Growth Amidst Challenges - TipRanks
Pfizer CEO Bourla ‘Cautiously Optimistic’ About Tariffs, Pricing Policies - insights.citeline.com
Untruths? Tariffs? For Pfizer CEO, Nothing Trumps National Security 04/30/2025 - MediaPost
JPMorgan maintains Pfizer stock Neutral with $30 target By Investing.com - Investing.com India
PFIZER INC : JP Morgan is Neutral - marketscreener.com
Pfizer Cuts Spending on Weaker Sales - marketscreener.com
Viking Therapeutics (VKTX) Sees Boost After Pfizer's Acquisition Plans - GuruFocus
Health Care Stocks Rise As Pfizer And AstraZeneca Lead Gains - Finimize
Pfizer could make ‘tremendous investments’ in the US, but here’s why it’s choosing not to - TradingView
Pfizer Earnings Beat Isn’t Enough to Ease Stock Worries - Barron's
Viking among notable gainers as Pfizer raises deal prospects - MSN
Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D - MSN
Pfizer Earnings: Expected Sales Decline Met With Solid Bottom-Line Growth From Cost Savings - Morningstar
Viking stock rises as Pfizer ups deal prospects (VKTX:NASDAQ) - Seeking Alpha
Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies - Endpoints News
Pfizer Stock’s 7% Yield Makes It Look Like a Junk Bond—But Better - Barron's
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.94%
자본화:
|
볼륨(24시간):